ICA-105574

CAS No. 316146-57-3

ICA-105574( ICA | 3-nitro-N-[4-phenoxyphenyl]-benzamide )

Catalog No. M24250 CAS No. 316146-57-3

ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 76 In Stock
10MG 132 In Stock
25MG 282 In Stock
50MG 444 In Stock
100MG 651 In Stock
500MG 1368 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ICA-105574
  • Note
    Research use only, not for human use.
  • Brief Description
    ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
  • Description
    ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ICA | 3-nitro-N-[4-phenoxyphenyl]-benzamide
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    hERG
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    316146-57-3
  • Formula Weight
    334.33
  • Molecular Formula
    C19H14N2O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Meng J , Shi C , Li L , et al. Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization[J]. European Journal of Pharmacology, 2013, 718(1-3):87-97.
molnova catalog
related products
  • DBPR112

    DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM for EGFRWT and 48 nM for EGFRL858R/T790M, capable of occupying the ATP-binding site and demonstrating significant antitumor efficacy.

  • LDC4297

    LDC4297 is a potent and selective CDK7 inhibitor.

  • CHMFL-EGFR-202

    CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).